Given its role in chemotherapy resistance, ERCC1-XPF has attracted interest as a potential biomarker for predicting treatment outcomes. Assessing the expression levels of ERCC1-XPF in tumors can help oncologists determine the likelihood of response to platinum-based therapies. Patients with low ERCC1-XPF expression are generally more responsive to these treatments, whereas those with high expression levels may require alternative therapeutic strategies.
